FDA Approves Oral Formulation of Edaravone to Treat ALS

The U.S. Food and Drug Administration (FDA) has approved an oral form of edaravone (Radicava ORS), for the treatment of amyotrophic lateral sclerosis (ALS), a rapid neurodegenerative disease. An intravenous (IV) formulation of edaravone was approved in 2017. ALS, also...

New CME Program Focused on MPS II (Hunter Syndrome)

  Barbara Burton, MD, Professor of Pediatrics at Northwestern University Feinberg School of Medicine, highlights the latest research about Mucopolysaccharidosis type II (MPS II; Hunter syndrome) presented at WORLDSymposium 2022. This free CME program provides...